Philip Mongelluzzo
Internal Medicine · Waterbury, CTNPI 1871563247
Payments from drug & device makers
Across 396 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AbbVie$991
- Novo Nordisk$707
- Boehringer Ingelheim$423
- AstraZeneca$310
- QOL Medical, LLC$273
- plus $1K from 28 others
What the payments were for
- Food & beverage$5,42499%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 90 | $1,426 |
| AbbVie(2 entities) | 113 | $991 |
| Novo Nordisk | 65 | $707 |
| Boehringer Ingelheim | 35 | $423 |
| AstraZeneca | 16 | $310 |
| QOL Medical, LLC | 9 | $273 |
| Amgen | 9 | $169 |
| GSK | 7 | $147 |
| Amarin Pharma, Inc. | 6 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $124 |
| Pfizer | 5 | $85 |
| Astellas Pharma US Inc | 4 | $79 |
| ANI Pharmaceuticals, Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $49 |
| Boston Scientific | 1 | $47 |
| Novartis | 2 | $43 |
| Mylan Specialty L.p. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| Lundbeck LLC | 2 | $35 |
| Exact Sciences | 1 | $29 |
| GRT US Holding, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| MDD US Operations, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Merck | 1 | $14 |
| Abbott | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,481 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 50 | $67,677 |
| EliquisApixaban | 68 | $61,992 |
| OzempicSemaglutide | 25 | $40,784 |
| XareltoRivaroxaban | 38 | $40,270 |
| JardianceEmpagliflozin | 33 | $37,245 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $23,860 |
| RybelsusSemaglutide | 25 | $22,955 |
| KerendiaFinerenone | 24 | $21,833 |
| VascepaIcosapent Ethyl | 61 | $20,930 |
| TradjentaLinagliptin | 12 | $18,786 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $13,539 |
| FarxigaDapagliflozin Propanediol | 15 | $11,399 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,201 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $4,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $14 | $105,07794 claims |
| Novo NordiskOzempic, Rybelsus | $707 | $63,73950 claims |
| PfizerEliquis | $85 | $61,99268 claims |
| Boehringer IngelheimJardiance, Tradjenta | $423 | $56,03145 claims |
| Johnson & JohnsonXarelto | $12 | $40,27038 claims |
| BayerKerendia | $1,426 | $21,83324 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $147 | $20,59737 claims |
| AstraZenecaFarxiga | $310 | $11,39915 claims |
| AbbVieSynthroid | $991 | $1,77725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Waterbury
- Joseph SouferWaterbury$21.5M
- Elie HelouWaterbury$184K
- Oltjon AlbajramiWaterbury$57K
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.